Drug Recalls

0 Class I (most serious) drug recalls reported in the last 30 days.

Medicine, company or reason Severity All classes Class I — most serious Class II Class III Status Any status Ongoing Completed Terminated Reported Last 30 days Last 90 days Last 12 months All on file Show recalls

1 recall

• Class II Completed October 2, 2024

  Mupirocin Ointment, USP, 2%, 22 g, Rx only, Manufactured by: Glenmark Pharmaceuticals, Ltd., Colvale-Bardez, Goa 403513, India. Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ, 07430, NDC 68462-180-22.

  Reason: Subpotent Drug

  Glenmark Pharmaceuticals Inc., USA · Mupirocin

  Lots, distribution and details

  Lots / codes

  Lot #: 19223615, 19223537, 19223544,19223568, 19223593,19223641, Exp. Date 08/2024; 19224055,19224281, 19224307, 19224321, 19224341, 19224467, Exp. Date 09/2024; 19224525, 19224542, 19224560,19224580, Exp. Date 10/2024; 19224990, 19224998, 19225014, 19225033, 19225293, 19225304, 19225320, 19225349, 19225367, 19225379, 19225401, Exp. Date 11/2024; 19230115, 19230123, 19230132, 19230137, 19230167, 19230170, Exp. Date 12/2024; 19230572, 19230607, 19230614, 19230628, 19230631, Exp. Date 1/2025; 19230874, 19230925,19230941, 19230957, 19230976,19231232, 19231238, 19231282,19231285, Exp. Date 02/2025.

  Distribution

  Product was distributed nationwide within the United States.

  Quantity

  2,031,480 ointments

  Recall started

  August 30, 2024 (Voluntary: Firm initiated)

  Severity

  Could cause temporary or medically reversible health problems; serious harm is unlikely.

  FDA recall number

  D-0660-2024

Have this medicine at home? Compare the lot number and expiry date on your package with the recall. Do not stop taking a prescribed medicine on your own — stopping suddenly can be riskier than the recalled lot. Your pharmacist can check it and usually swap it for an unaffected one.

What the recall classes mean

• Class I Most serious: use could cause serious health problems or death.
• Class II Could cause temporary or medically reversible health problems; serious harm is unlikely.
• Class III Not likely to cause health problems — for example a labelling or packaging fault.

Source: FDA Enforcement Report, via openFDA. Updated here twice a day; last update October 31, 2026 14:40. openFDA data are not validated for clinical use — confirm with the FDA source or your pharmacist.